key: cord-0305115-l0583cmp
authors: Esparcia-Pinedo, L.; Yarci-Carrion, A.; Mateo-Jimenez, G.; Ropero, N.; Gomez-Cabanas, L.; Lancho-Sanchez, A.; Martin-Gayo, E.; Sanchez-Madrid, F.; Moldenhauer, F.; Gutierrez-Cobos, A.; Real de Asua, D.; Alfranca, A.
title: Development of an effective immune response in adults with Down Syndrome after SARS-CoV-2 vaccination
date: 2022-01-16
journal: nan
DOI: 10.1101/2022.01.14.22269303
sha: c71964d36641243fc23ebcace30cc1b795618e34
doc_id: 305115
cord_uid: l0583cmp

Immune dysregulation in individuals with Down syndrome (DS) leads to an increased risk for hospitalization and death due to COVID-19 and may impair the generation of protective immunity after vaccine administration. The cellular and humoral responses of 55 DS patients who received a complete SARS-CoV-2 vaccination regime at one to three (V1) and six (V2) months were characterised. SARS-CoV-2-reactive CD4+ and CD8+ T lymphocytes with a predominant Th1 phenotype were observed at V1, and increased at V2. Likewise, a sustained increase of SARS-CoV-2-specific circulating Tfh (cTfh) cells was observed one to three months after vaccine administration. Specific IgG antibodies against SARS-CoV-2 S protein were detected in 96% and 98% of subjects at V1 and V2, respectively, though IgG titers decreased significantly between both timepoints.

(#) These authors share senior authorship 23 (&) The new coronavirus disease (COVID-19) due to SARS-CoV-2 is a global health 53 emergency since March 2020. Although COVID-19 entails no or mild symptoms in most 54

individuals, several at-risk patient subgroups develop a severe form of the disease, 55

leading to acute respiratory distress syndrome (ARDS) (Brodin, 2021; Ruan et al., 2020) . 56

Individuals with Down syndrome (DS), the most frequent chromosomal abnormality 57

worldwide, are particularly vulnerable to the disease, with a 4-fold increased risk for 58 COVID-19-related hospitalization and a 3 to 10-fold increased risk for COVID-19-related 59 mortality (Clift et al., 2021; Hüls et al., 2021; Wadman, 2020) . 60 61

Although this increase can be partially attributed to a higher prevalence of comorbidities 62 associated with a poorer COVID-19-related prognosis, such as obesity, congenital heart 63 disease (CHD) or respiratory diseases (Perera et increase in IFNAR1 and IFNAR2 expression in different cell types from DS donors has 72 been described (Kong et al., 2020) . Cells from DS patients also present variable degrees 73 of increased IFN-I proximal signaling, such as higher levels of pSTAT1 (Malle and 74 Bogunovic, 2021). Furthermore, the increased expression of TMPRSS2, which primes 75 the viral S protein for entry into host cells and is also encoded in HSA21, may facilitate 76 the infection of target cells by SARS-CoV-2, while NLRP3 downregulation and increased 77 IL-10 production could be involved in the higher risk of bacterial infectious complications 78 in these patients (De Toma and Dierssen, 2021; Espinosa, 2020) . DS individuals also 79 have high basal levels of proinflammatory cytokines like IL-2, IL-6, or TNF- which may 80 enhance the "cytokine storm" that underlies ARDS in this condition (Espinosa, 2020) .

Although the overall effect of these alterations seems deleterious and provides some 82 proof for the worse outcomes following SARS-CoV-2 infection, the net balance between 83 all these interplaying factors is far from clear. We performed a characterization of cellular and humoral responses developed in DS 104

patients at one to three (V1) and six (V2) months after two-dose SARS-CoV-2 105 vaccination. We provide evidence of the presence of SARS-CoV-2-reactive CD4+ and 106 CD8+ T lymphocytes with a predominant Th1 phenotype in V1, which increased in V2.

Likewise, a sustained increase of SARS-CoV-2-specific circulating Tfh (cTfh) cells was 108 observed in these patients one to three months after vaccine administration. Specific IgG 109

antibodies against SARS-CoV-2 S protein were detected in V1, which significantly 110 decreased in V2.

RESULTS AND DISCUSSION 113 114

T cell response to SARS-CoV vaccination in DS donors 115

To assess immune response elicited by SARS-CoV-2 vaccine in DS, we recruited 55 116 donors whose demographic and clinical characteristics are shown in Table 1 . These 117 donors were inoculated with two doses of a SARS-CoV-2 vaccine following the 118 recommended schedule (vaccine types, described in Table 1) , and both T cell and 119

antibody responses were analyzed before vaccine administration (V0), one to three 120 months (V1) and six months (V2) after second vaccination. Fifty-one subjects (51/55, 121 93%) were enrolled after having received at least one vaccination dose. To avoid any 122 delay in official vaccination strategies, we admitted the use in these cases of biobank-123 stored samples (from earlier than February 2020) as baseline (V0). Median time 124

(interquartile range) from the last dose of the recommended vaccination schedule to the 125 first blood extraction (V1) was 62 (42-70) days, and 159 (150-172) days to the second 126 blood extraction (V2). 127

We determined the presence of SARS-CoV-2-specific T cells in V0, V1 and V2. To 128 assess the percentage of responsive T cells, we used an activation-induced marker 129

(AIM) assay based on the detection of CD4+ OX40/CD137 double positive and CD8+ 130 CD69/CD137 double positive cells, after 24h in the presence of peptide pools from 131 SARS-CoV-2 (NCAP, S1, S2, RBD domain, VME1 and Mpro proteins for V0 and S1, S2, 132

and RBD domain for V1 and V2). In all cases, we included a human actin-derived peptide 133 pool as a negative control, and Staphylococcal enterotoxin B (SEB) as a positive control. 134

As shown in Fig.1 , we found a predominant CD4+ response (73.21% patients with 135 specific CD4+ vs.16.36% patients with specific CD8+ in V2), which is in line with previous 136 data in non-DS individuals (Grifoni et al., 2020) . Of note, CD4+ activation against S1 and 137 S2 was observed in a single pre-pandemic sample from V0 (Fig. 1A) . We did not detect 138 SARS-CoV-2-specific CD8+ lymphocytes in this baseline visit (Fig. 1B) . SARS-CoV-2 S-139 responsive CD4+ cells have also been previously detected in healthy non-DS donors, 140

and their presence is explained by a possible cross-reaction with common cold 141 coronaviruses or other pathogens which contain SARS- to 16.36% in V2 for CD8+. We could detect vaccine-elicited specific CD4+ and CD8+ directed against S1, S2 and RBD, with a similar pattern in V1 and V2 (Fig. 1A, B ). T cell 158 responses seem to be delayed in comparison to non-DS donors, which usually reach a 159

higher percentage of individuals with specific T cell immunity within 4-7 weeks post 160 SARS-CoV-2 vaccine administration (Esparcia-Pinedo L et al., 2022). 161 SARS-CoV-2 mRNA vaccines are known to promote a Th1 reaction in the general 162

population (Sadarangani et al., 2021) . Because individuals with DS usually present a 163

higher Th1/Th2 ratio than euploid donors, a finding related to an increase in baseline 164

IFN levels in this population (Franciotta et al., 2006) , we sought to determine whether 165 vaccination also resulted in Th1 predominant response in these patients. We evaluated 166

T helper populations in SARS-CoV-2-specific CD4+ lymphocytes and found comparable 167

percentages of Th1 and Th2 in V1. However, a significant increase in Th1 but not Th2 168 could be observed in V2 (p<0.01). As a specificity control, we determined Th1 and Th2 169 distribution in SEB-stimulated CD4+ cells, and found no significant differences between 170

both subsets in either V1 and V2 ( Fig. 2A) . A similar pattern was detected regardless of 171 the peptide pool (S1 or S2) analyzed (Fig. 2B ). In addition, we did not find gender 172 differences in Th1 and Th2 behavior, except for a significantly higher Th2 response in 173 V1 in male DS donors (Suppl. Fig. 2A ). Of note, although Th1 increase in V2 could be 174 observed in all DS individuals, it was higher in patients < 40 years of age (Suppl. Fig.  175 2B). 176

collaborates in the activation and proliferation of B cells and the generation of high-affinity 178

antibodies. In DS, normal counts of Tfh with a reduced B helper capacity have been 179

reported. However other authors show increased percentages of IFN-secreting Tfh 180 (Tfh1), which are thought to promote autoimmune responses in these patients (Ottaviano 181 et al., 2020). In vaccinated DS donors, we found a SARS-CoV-2-specific cTfh population 182

with sustained levels between V1 and V2 (Fig. 3A) . PD-1hi cTfh are thought to represent 183 a subset of recently activated cTfh cells (Dan et al., 2021) . Accordingly, we detected 184 SARS-CoV-2-specific CD4+CXCR5+PD-1hi cells in V1 in DS donors, whose levels were 185 slightly reduced in V2 (Fig. 3A) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint the whole sample, though it was only statistically significant in the subgroup of individuals 224 older than 40 years (Fig. 4C) . Our results show an uncoupled humoral and cellular 225 response in these patients, with antibody titers peaking already at V1, whereas T cell 226 activation peaks at V2 (Fig.4) . A dissociation between both arms of adaptive immunity 227

has also been described in euploid individuals infected with SARS-CoV-2, and the 228 development of an overt antibody response is not always accompanied by detectable T 229 cell specific activation (Grifoni et al., 2020) .

Our findings show that an immune adaptive response is achieved in DS individuals three 232 months after SARS-CoV-2 vaccination lasting, at least, up to six months after 233

vaccination. The degree of protection conveyed by these vaccination-elicited 234

immunological changes should nonetheless be carefully interpreted. Recent reports still 235

show an increased hazard ratio for COVID-19 hospital admission (2.55-fold increase) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint peptides from S1, S2 and RBD from spike (S) protein, VME1 (membrane protein), NCAP 308

(nucleoprotein) and Mpro (Cys-like protease, nsp5) (1μg/ml) in V0, and S1, S2 and RBD 309

for V1/V2. A positive control with staphylococcal enterotoxin B (SEB; Sigma Aldrich) 310

(1μg/ml), and a negative control with human β-actin peptide pool (PepMixTM; JPT 311

Peptide Technologies) (1μg/ml) were included. 312

After stimulation, cells were incubated with anti-human CD3-PECy7/CD4-Pacific 314

Orange/CD69-FITC/CXCR5-BV605/PD-1-BV786/CCR6-PerCP (BD Becton 315 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 16, 2022. ; https://doi.org/10.1101/2022.01.14.22269303 doi: medRxiv preprint Dickinson)/CD137-BV711/OX40-PE/CXCR3-APCH7 (Biolegend)  for  30 min. 316

Subsequently, cells were washed and finally resuspended in 200μl PBS 1x. All the 317 samples were acquired on a BD FACSCanto II flow cytometer (BD Becton Dickinson). 318

The gating strategy for stimulated T cells is provided in Suppl Fig. 1 : CD4+ T cells were 319 identified as positive for CD3 and CD4 markers. Activated CD4+ cells were defined as 320 double positive for OX40 and CD137. SARS-CoV-2-responsive Th1 and Th2 were 321 defined as OX40+CD137+ cells within CXCR3+CCR6-and CXCR3-CCR6-subsets 322

respectively. SARS-CoV-2-specific cTfh cells were defined as OX40+CD137+ double 323 positive cells within CD4+CXCR5+ and CD4+CXCR5+PD-1hi populations. CD8+ T cells 324

were identified as positive for CD3 and negative for CD4 staining, and activated CD8+ 325 defined as CD69 and CD137 double positive cells. Flow cytometry data were analyzed 326

using FlowJo software (BD Becton Dickinson). 327

Specific T cell response was determined by subtracting the percentage of either CD4+ 328 OX40+CD137+ or CD8+ CD69+CD137+ in the presence of β-actin peptides from that 329 obtained with SEB or SARS-CoV-2 peptides (specific percentage). A positive result was 330 considered for samples with specific percentage equal or above the median two-fold 331 standard deviation of all negative controls (0.82% for OX40/CD137 and 0.93% for 332 CD69/CD137). 333

This project was approved by the institutional IRB at La Princesa University Hospital 335 (register number: 4386), meets international standards of data protection and is in line 336

with general good practice guidelines and those established in the Declaration of 337

Helsinki. 338

Categorical data were described as frequencies (percentages) and quantitative 340

variables, as mean (SD) or median (IQR). Quantitative variables were represented in bar 341

graphs as mean ± standard deviation (SD), or in box-and-whiskers plots. For comparison 342

between populations, analysis of variance was performed. To analyze statistically 343 significant differences in variables following a non-normal distribution, Kruskal-Wallis test 344

for unpaired samples and Friedman test for paired samples were used. The statistical 345 significance threshold was set at p < 0·05. All data analyses were perfomed using Graph 346

Pad is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 16, 2022. ; https://doi.org/10.1101/2022.01.14.22269303 doi: medRxiv preprint S2-specific (right) Th1 and Th2 CD4+ subsets in visits 1 and 2. Mean+SD is shown. 537 *p<0.05; **p<0.01; ns, non-significant. 538 show the percentage of SARS-CoV-2-specific CD8+CXCR5+ (left) and PD-1hi 542 expression within CD8+CXCR5+ population (right) in visits 1 and 2 (n=11). *p<0.05; 543 **p<0.01; ns, non-significant. 544 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 16, 2022. ; 

Immune determinants of COVID-19 disease presentation and severity

Reduced numbers of switched memory B cells with high terminal 389 differentiation potential in Down syndrome

Interferon-Driven Immune 391 Dysregulation in Down Syndrome: A Review of the Evidence

Mortality Risk in Down Syndrome: Results From a Cohort Study of 8 Million Adults

Antibody response to 398 pneumococcal capsular polysaccharide vaccine in Down syndrome patients

Immunological memory 403 to SARS-CoV-2 assessed for up to 8 months after infection

Network analysis of Down syndrome and SARS-CoV-2 405 identifies risk and protective factors for COVID-19

Antibody responses to the 408 BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Declining 411 antibody levels after hepatitis B vaccination in Down syndrome: A need for booster 412 vaccination

CD4+ T cell Immune specificity changes after 416 vaccination in healthy and COVID-19 convalescent subjects

Down Syndrome and COVID-19: A Perfect Storm?

419 Interferon-gamma-and interleukin-4-producing T cells in Down's syndrome

Targets 424 of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and 425 Unexposed Individuals

Risk prediction of covid-429 19 related death and hospital admission in adults after covid-19 vaccination: national 430 prospective cohort study

Immune Dysregulation in Children With Down 432 Syndrome

An international survey on the impact of COVID-19 437 in individuals with Down syndrome

Medical vulnerability of individuals 442 with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society 443 and the UK ISARIC4C survey

Immune evaluation and vaccine 445 responses in Down syndrome: evidence of immunodeficiency?

Three Copies of Four 450 Interferon Receptor Genes Underlie a Mild Type I Interferonopathy in Down Syndrome

Down syndrome and type I interferon: not so simple

CoV-2 T cell epitopes in unexposed humans

Clinical 462 evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM 463 assays among infected, recovered, and vaccinated groups

A 466 prevalent CXCR3(+) phenotype of circulating follicular helper T cells indicates humoral 467 dysregulation in children with Down syndrome

Genetic mechanisms of critical illness in COVID-19

COVID-19 deaths in people 483 with intellectual disability in the UK and Ireland: descriptive study

2021. 486 Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose 487 BNT162b2 vaccine

Comparison of COVID-19 and Non-COVID-19 Pneumonia 491 in Down Syndrome

Clinical predictors of mortality due to 493 COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Immunological mechanisms of vaccine-496 induced protection against COVID-19 in humans

Quantitative, Phenotypical, and Functional Characterization of Cellular 499 Immunity in Children and Adolescents With Down Syndrome

Robust T Cell 506 Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Establishment of the WHO International Standard and Reference 509 Panel for anti-SARS-CoV-2 antibody

CXCR5+ CD8 T Cells: Protective or Pathogenic? Front 513 Immunol

Generation of switched memory B cells in 516